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treatment until allo-HSCT (indicated in poor responders to induction; MRD ￿ 10−3) for patients being
treated for late BCP-ALL bone marrow relapses (n = 413; median follow-up, 9.4 years) in the ALL-REZ
BFM 2002 trial/registry (ClinicalTrials.gov identifier: NCT00114348). RESULTS Patients with both
good (MRD < 10−3) and poor responses to induction treatment reached excellent event-free survival
(EFS; 72% v 65%) and overall survival (OS; 82% v 74%). Patients with MRD of 10−2 or greater after
induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more frequently than it did
in patients with MRD of 10−3 or greater to less than 10−2 (P = .037). Patients with 25% or more leukemic
blasts after induction (early nonresponders) had the poorest prognosis (EFS, 22%). Interestingly, patients
with MRD of 10−3 or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS
of 63%, which in principle justifies allo-HSCT in these patients. From a panel of selected candidate
genes, TP53 alterations (frequency, 8%) were the only genetic alteration with independent prognostic
value in any MRD-based response subgroup. CONCLUSION After induction treatment, MRD-based
treatment stratification resulted in excellent survival in patients with late relapsed BCP-ALL. Prognosis
could be further improved in very poor responders by intensifying treatment directly after induction.
TP53 alterations can be defined as a novel genetic high-risk marker in all MRD response groups in late
relapsed BCP-ALL. Here we identified early and late nonresponders to be considered as events in future
trials.
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abstract
PURPOSE Minimal residual disease (MRD) helps to accurately assess when children with late bone marrow
relapses of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) will beneﬁt from allogeneic hemato-
poietic stem-cell transplantation (allo-HSCT). More detailed dissection of MRD response heterogeneity and the
speciﬁc genetic aberrations could improve current practice.
PATIENTS AND METHODS MRD was assessed after induction treatment and at different times during relapse
treatment until allo-HSCT (indicated in poor responders to induction; MRD$ 1023) for patients being treated for
late BCP-ALL bone marrow relapses (n = 413; median follow-up, 9.4 years) in the ALL-REZ BFM 2002 trial/
registry (ClinicalTrials.gov identiﬁer: NCT00114348).
RESULTS Patients with both good (MRD , 1023) and poor responses to induction treatment reached excellent
event-free survival (EFS; 72% v 65%) and overall survival (OS; 82% v 74%). Patients with MRD of 1022 or greater
after induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more frequently than it did in
patients with MRD of 1023 or greater to less than 1022 (P = .037). Patients with 25% or more leukemic blasts
after induction (early nonresponders) had the poorest prognosis (EFS, 22%). Interestingly, patients with MRD of
1023 or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS of 63%, which in principle
justiﬁes allo-HSCT in these patients. From a panel of selected candidate genes, TP53 alterations (frequency,
8%) were the only genetic alteration with independent prognostic value in any MRD-based response subgroup.
CONCLUSION After induction treatment, MRD-based treatment stratiﬁcation resulted in excellent survival in
patients with late relapsed BCP-ALL. Prognosis could be further improved in very poor responders by intensifying
treatment directly after induction. TP53 alterations can be deﬁned as a novel genetic high-risk marker in all MRD
response groups in late relapsed BCP-ALL. Here we identiﬁed early and late nonresponders to be considered as
events in future trials.
J Clin Oncol 37:3493-3506. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Contemporary intensive combination chemotherapy
and the risk-adapted indication for allogeneic hema-
topoietic stem-cell transplantation (allo-HSCT) has
brought event-free survival (EFS) and overall survival
(OS) to approximately 50% and 60%, respectively, for
children and adolescents with relapsed acute lym-
phoblastic leukemia (ALL).1-3 Time to relapse is the
strongest predictor of outcome and is used in most
protocols for risk stratiﬁcation at relapse in combina-
tion with immunophenotype and relapse site.1-6 Pa-
tients with late relapses of B-cell precursor ALL (BCP-
ALL) and bone marrow involvement have intermediate
risk. Patients with early combined or isolated extra-
medullary BCP-ALL relapses are also classiﬁed as
intermediate risk because they achieve better EFS
than patients with very early or early isolated bone
marrow relapses. The ALL-REZ BFM P95/96 trial
identiﬁed minimal residual disease (MRD) after in-
duction treatment as the strongest prognostic factor for
intermediate-risk relapsed ALL.7 MRD of less than
1023 after induction predicted 10-year EFS greater
than 70% and supported the continuation of consol-
idation and maintenance chemotherapy, whereas
MRD of 1023 or greater predicted 10-year EFS of less
than 20% with conventional intensive combination
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chemotherapy alone.7-9 Therefore, an MRD-based strategy
to intensify treatment with allo-HSCT after consolidation
therapy in patients with intermediate-risk relapses and
MRD of 10–3 or greater after induction was implemented in
the ALL-REZ BFM 2002 (ClinicalTrials.gov identiﬁer:
NCT00114348) trial and substantially improved outcome
(8-year EFS, 64% v 18% in the historical control) in patients
with MRD-based poor response.9 However, patients with
early intermediate-risk relapses had poor prognoses even
if they responded well to induction (MRD , 1023), and
were recommended to receive allo-HSCT.9 The impact of
response heterogeneity, kinetics, and genetic variation of
patients in the ALL-REZ BFM 2002 trial was not addressed
in the early report.
Here we provide more detailed subgroup analyses for
patients with late bone marrow relapses uniformly treated
according to the ALL-REZ BFM 2002 protocol with data
from a substantially extended patient cohort and doubled
follow-up time.9 Our central question was whether the
current stratiﬁcation strategy is adequate for all subgroups
of patients with late BCP-ALL relapses or whether there are
patient subgroups for whom treatment strategies should be
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FIG 1. CONSORT diagram of patients with late B-cell precursor acute lymphoblastic leukemia bone
marrow relapses for minimal residual disease (MRD) after induction treatment, allogeneic hematopoietic
stem-cell transplantation (allo-HSCT) indication according to trial protocol, and allo-HSCT history. MRD-
based response to induction was applied in the ALL-REZ BFM 2002 trial and the ALL-REZ BFM Registry
protocol for patient stratiﬁcation to therapy intensiﬁcation with allo-HSCT. Of the 190 patients with MRD
good response, a small proportion of patients (11%; 21 of 185 with available data) received an allo-HSCT,
and allo-HSCT from matched sibling donor was allowed (12 of 21); however, allo-HSCT from a matched
unrelated donor (MUD; 9 of 21) was not recommended. Of the 173 patients with an indication for allo-
HSCT, 17% (29 of 167) did not undergo an allo-HSCT. Reasons for not undergoing allo-HSCT in the 29
patients were patients or guardians refused the treatment (n = 5), no suitable donor was found (n = 7), an
event occurred before reaching allo-HSCT (n = 13), pretreatment toxicity burden prevented transplantation
(n = 3), and treatment was continued in another country (n = 1).
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changed in future trials. The prognostic relevance of dif-
ferent MRD levels after induction treatment and MRD ki-
netics between induction at relapse and allo-HSCT in
second clinical remission (CR2) were investigated in ad-
dition to the prognostic relevance of genetic subgroups
determined from a panel of selected candidate genes.
PATIENTS AND METHODS
This study included children and adolescents (median age,
9.7 years at relapse diagnosis; interquartile range, 7.1 to 14.2
years; maximum, 25.7 years; patients age 18 years or older,
n = 30) with late bone marrow BCP-ALL relapses diagnosed
between January 1, 2002, and December 31, 2015. Late
bonemarrow relapse was deﬁned as disease recurrence with
or without extramedullary involvement, diagnosed 6 months
or more after completing ﬁrst-line treatment or 30 months or
more from initial diagnosis (Data Supplement).
Study participants were treated according to the
intermediate-risk group arm of the ALL-REZ BFM 2002 trial
and the subsequent the ALL-REZ BFM registry (since
October 2012). Trials were approved by the local ethics
committees and informed consent was given by patients
and/or guardians before enrollment and treatment. Patients
with MRD of 10–3 or greater after induction at relapse were
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FIG 2. Survival differs between two subgroups of good responders to induction. (A) Kaplan-Meier analysis estimating the event-free survival (EFS) at
10 years in patients who responded well to induction treatment. (B) Competing risk analysis of cumulative incidence of subsequent relapses (CIR) and
cumulative incidence of treatment-related deaths (CID) at 10 years in patients who responded well to induction. (C) Kaplan-Meier analysis estimating the
10-year overall survival (OS) in patients who responded well to induction. Minimal residual disease (MRD) in bone marrow was used to more ﬁnely divide
good response into two groups (MRD , 1024 and MRD $ 1024 to , 1023) after induction.
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recommended for allo-HSCT in CR2 from amatched sibling
or matched unrelated donor ($ 9 of 10 identical HLA al-
leles). Patients with MRD of less than 10–3 continued to
receive consolidation and maintenance chemotherapy, but
allo-HSCT from a matched sibling donor was also permitted.
Most patients receiving allo-HSCT were enrolled into the
ALL-SCT 2003 and ALL-SCT BFM international trials.10
Multiple bone marrow samples were collected between
relapse diagnosis and allo-HSCT (Data Supplement), of
which the analyses presented here primarily compare
samples collected after induction treatment and 30 days or
fewer before allo-HSCT. MRD was assessed by real-time
quantitative polymerase chain reaction (PCR) using T-cell
receptor or immunoglobulin gene rearrangements as de-
scribed previously.9,11 Data were analyzed according to the
EuroMRD Consortium guidelines.12 Real-time PCR and/or
ﬂuorescence in situ hybridization (FISH) were used to
detect gene fusions or translocations common in pediatric
ALL, including ETV6-RUNX1, TCF3-PBX1, BCR-ABL1,
MLL-AFF1, and MLL-MLLT1. High-hyperdiploidy and hy-
podiploidy were ﬂow cytometrically identiﬁed by DNA index
and/or multiplex ligation-dependent probe ampliﬁcation
(SALSA multiplex ligation dependent probe ampliﬁca-
tion [MLPA] P181 Centromere probe mix; MRC Holland,
Amsterdam, the Netherlands). Copy number alterations in
EBF1, IKZF1, CDKN2A, CDKN2B, PAX5, ETV6, BTG1,
RB1, and the PAR1 region were detected by using the
SALSA MLPA P335 ALL-IKZF1 probe mix (MRC Holland).
The resulting P2RY8-CRLF2 fusion was validated by re-
verse transcription PCR for PAR1 deletions. TP53 deletions
were detected by using the SALSA MLPA P056 probe mix
and were conﬁrmed by FISH. Mutations in key TP53,
KRAS, NRAS, and FLT3 exons were identiﬁed by Sanger
sequencing.13-15
Distributions of clinical and genetic variables among dif-
ferent MRD subgroups were compared by x2 or Fisher’s
exact test for categorical variables and by Mann-Whitney U
or Kruskal-Wallis tests for continuous variables. EFS and OS
were analyzed by using Kaplan-Meier analysis and a two-
tailed log-rank test. Cumulative incidence of competing
risks, cumulative incidence of subsequent relapse (CIR),
and cumulative incidence of therapy-related death (CID)
were assessed by using the Kalbﬂeisch-Prentice method
and Gray statistics. Multivariable Cox regression included
variables considered to be relevant for outcome or asso-
ciated with MRD response to induction treatment for 30 days
or fewer before allo-HSCT in stepwise forward testing.
Models were compared by using the log likelihood-ratio
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FIG 3. Patterns of genetic alterations in the bone marrow relapse are heterogeneous among different response subgroups. The oncoplot visually compares
genetic alterations detected in the bonemarrow relapse.25,26 Relapse genomics are sorted according to minimal residual disease (MRD)–based response in
patients to induction treatment. Response to induction was divided into the ﬁve ﬁner subdivisions detected in survival analysis: early nonresponse ($ 25%
leukemic blasts), poorB (, 25% leukemic blasts but MRD$ 1022), poorA (MRD$ 1023 to, 1022), goodB (MRD$ 1024 to, 1023), and goodA (MRD,
1024). Color denotes the presence of recurrent fusion genes (purple), high hyperdiploidy or hypodiploidy (olive), mutations (brown), gene deletions
(turquoise), subsequent event (black), or no data (black dots).
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TABLE 1. Clinical and Genetic Parameters and Their Association With Outcome
Parameters
EFS at 10 Years
Total No. of Patients EFS, % 95% CI P* HR 95% CI P**
Sex .75
Male 199 68.7 62 to 75 1.00
Female 164 67.5 60 to 74 1.06 0.73 to 1.50 .75
Quartiles for age at diagnosis of relapse, years .25
, 7.1 98 71.0 61 to 79 1.00
$ 7.1 to , 9.7 84 72.5 61 to 81 0.87 0.50 to 1.53 .64
$ 9.7 to , 14.2 92 70.5 60 to 79 1.03 0.61 to 1.74 .90
$ 14.2 89 58.8 47 to 69 1.43 0.87 to 2.36 .15
Quartiles for time from initial diagnosis to diagnosis
of relapse, months
.20
, 36.4 90 65.1 54 to 74 1.00
$ 36.4 to , 43.3 92 63.3 52 to 72 1.09 0.67 to 1.79 .72
$ 43.3 to , 56.5 90 70.7 59 to 79 0.76 0.45 to 1.29 .31
$ 56.5 91 73.8 63 to 82 0.66 0.38 to 1.12 .13
Quartiles for time from end of ﬁrst-line treatment to
diagnosis of relapse, months
.30
, 12.0 91 63.2 52 to 72 1.00
$ 12.0 to , 18.9 91 66.2 55 to 75 0.92 0.56 to 1.50 .74
$ 18.9 to , 32.1 91 69.8 59 to 79 0.74 0.44 to 1.23 .25
$ 32.1 90 73.5 63 to 82 0.62 0.37 to 1.06 .083
Site of relapse .73
Isolated to bone marrow 284 67.5 62 to 73 1.00
Extramedullary and bone marrow 79 70.7 59 to 79 0.92 0.58 to 1.16 .73
Immunophenotype .22
Pro-B ALL 14 64.3 34 to 83 1.00
Common ALL 251 70.1 64 to 75 0.79 0.32 to 1.95 .61
Pre-B ALL 57 68.4 42 to 68 1.27 0.48 to 3.33 .63
Biphenotypic 7 60.0 13 to 88 0.68 0.13 to 3.51 .65
HSCT .0012
No 183 58.9 52 to 66 1.00
Yes 159 76.3 69 to 82 0.52 0.35 to 0.78 .001
Unknown 21
Donor for HSCT .0078
Matched family 41 89.7 75 to 96 1.00
Matched unrelated 113 73.0 64 to 80 3.16 1.11 to 8.98 .031
Mismatched 5 80 5 to 75 8.73 1.95 to 39.1 .005
Genetic characteristics of relapses
ETV6-RUNX1 gene fusion .012
Negative 231 64.2 58 to 70 1.00
Positive 80 79.7 69 to 87 0.51 0.30 to 0.87 .013
BCR-ABL1 gene fusion .33
Negative 299 68.4 63 to 73 1.00
Positive 8 87.5 39 to 98 0.39 0.054 to 2.79 .35
(continued on following page)
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TABLE 1. Clinical and Genetic Parameters and Their Association With Outcome (continued)
Parameters
EFS at 10 Years
Total No. of Patients EFS, % 95% CI P* HR 95% CI P**
TCF3-PBX1 gene fusion
Negative 240
Positive 1 — — —
MLL-AF4 gene fusion
Negative 304
Positive 2 — — —
Other MLL gene fusion .81
Negative 260 65.8 59 to 71 1
Positive 8 62.5 23 to 86 1.15 0.36 to 3.6 .82
P2RY8-CRLF2 gene fusion .31
Negative 233 66.2 60 to 72 1
Positive 8 50.0 15 to 75 1.68 0.61 to 4.6 .31
High hyperdiploidy .037
Negative 192 63.9 57 to 70 1
Positive 51 80.3 66 to 89 0.50 0.26 to 0.97 .041
Low hyperdiploidy .79
Negative 228 67.3 61 to 73 1
Positive 15 66.7 38 to 85 1.13 0.46 to 2.79 .79
Hypodiploidy .011
Negative 239 68.0 62 to 74 1
Positive 4 25.0 9 to 67 4.01 1.25 to 12.8 .019
IKZF1 loss .51
No 164 66.9 59 to 74 1
Yes 79 62.8 51 to 72 1.17 0.74 to 1.83 .51
CDKN2A/B loss .33
No 170 64.0 56 to 71 1
Yes 73 69.4 57 to 79 0.79 0.48 to 1.28 .33
ETV6 loss .69
No 173 64.4 57 to 71 1
Yes 71 68.8 57 to 78 0.90 0.55 to 1.47 .68
PAX5 loss .96
No 194 65.6 59 to 72 1
Yes 49 64.9 50 to 77 1.01 0.59 to 1.72 .96
BTG1 loss .39
No 207 66.3 59 to 72 1
Yes 35 60.0 42 to 74 1.28 0.72 to 2.28 .39
RB1 loss .68
No 220 65.1 58 to 71 1
Yes 22 68.2 45 to 83 0.85 0.39 to 1.84 .68
EBF1 loss .38
(continued on following page)
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test. For EFS analysis, subsequent relapse, therapy-related
death, secondary malignancies, and patients who did not
achieve morphologic remission after 10 weeks of treatment
(nonresponse) were considered adverse events. Time to
event was estimated from the dates of relapse diagnosis to
event. Death before achieving a remission (death as a result of
induction treatment) or nonresponse was categorized as event
with zero time to event. EFS, OS, CIR, and CID stated in our
analyses always correspond to 10-year observation time. Sta-
tistical analyses were conducted using SPSS version 23
(SPSS, Chicago, IL), STATA version 14.2 statistical software
(STATA, College Station, TX), and R version 3.3.2 for sta-
tistical computing. A two-sided P value , .05 was consid-
ered signiﬁcant.
RESULTS
Clinical Characteristics
A total of 413 children and adolescents with late bone
marrow ALL relapses were enrolled in the study (Fig 1).
Median follow-up time was 9.4 years (95% CI, 8.8 to 10.2
years). Overall EFS and OS were 67% (95% CI, 62% to
71%) and 76% (95% CI, 72% to 80%), respectively (Data
Supplement). Forty-one patients were excluded from fur-
ther analyses because of death as a result of induction
treatment or lack of MRD data after induction (Fig 1). In the
remaining cohort (n = 372), shorter time to relapse was
associated with poorer response to induction treatment or
nonresponse as the event after relapse (Data Supplement).
International trials for treatment of relapses have used
different cutoffs deﬁning late relapse at 30 or 36 months
after diagnosis to relapse. However, survival in patients who
relapsed either between 30 and 36 months after diagnosis
or at 36 months or more did not signiﬁcantly differ in our
cohort, supporting that patients relapsing between 30 and
36months after initial diagnosis are adequately categorized
as intermediate risk and not high risk, for patients who
received ﬁrst-line therapy based on the ALL BFM or
COALLtrials (Data Supplement). Thismight not be the same
after other ﬁrst-line therapies.
TABLE 1. Clinical and Genetic Parameters and Their Association With Outcome (continued)
Parameters
EFS at 10 Years
Total No. of Patients EFS, % 95% CI P* HR 95% CI P**
No 227 66.2 60 to 72 1
Yes 16 56.3 30 to 76 1.42 0.65 to 3.07 .38
TP53 loss .0031
No 222 67.8 62 to 74 1
Yes 11 36.4 11 to 63 3.07 1.40 to 6.69 .005
TP53 mutation .015
No 233 68.3 62 to 74 1
Yes 12 41.2 15 to 67 2.53 1.16 to 5.51 .019
NRAS mutation .32
No 225 65.8 59 to 72 1
Yes 22 77.3 54 to 90 0.63 0.26 to 1.57 .32
KRAS mutation .71
No 234 66.8 60 to 72 1
Yes 13 68.4 34 to 87 0.83 0.30 to 2.25 .71
FLT3 mutation .48
No 198 69.0 62 to 75 1
Yes 7 57.1 17 to 84 1.52 0.48 to 4.84 .48
TP53 loss and mutation .0052
No 225 69.0 62 to 75 1
Yes 20 45.0 23 to 65 2.42 1.28 to 4.58 .007
Abbreviations: EFS, event-free survival; HR, hazard ratio; HSCT, hematopoietic stem-cell transplantation; pre-B ALL, pre-B-cell acute lymphoblastic
leukemia; pro-B ALL, pro-B-cell acute lymphoblastic leukemia.
*Log-rank test.
**Cox regression.
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About half the patients (190 of 372; 51%) responded well
(MRD of less than 10–3), whereas 182 patients (49%; MRD
$ 1023) responded poorly to induction treatment (Fig 1).
Among patients with available morphology data after
induction, 97.5% of patients (363 of 372) had less than
25% leukemic blasts and nine patients hadmore than 25%
leukemic blasts in the bone marrow after induction. EFS
was signiﬁcantly lower in these nine patients (22%; 95%CI,
4% to 51%; Data Supplement). Taken together, late bone
marrow ALL relapses occurred over a wide time range after
cessation of ﬁrst-line therapy, and a shorter time to relapse
was correlated with poor MRD response to induction and
subsequent nonresponse. Even though about half of all
patients with late bone marrow BCP-ALL relapses had poor
MRD-based responses to induction, EFS was favorable in
the entire group.
Prognostic Subgroups in Good Responders to Induction:
GoodA (MRD < 1024) Versus GoodB (MRD ‡ 1024 to < 1023)
In patients who responded well to induction treatment
(MRD , 1023), the EFS was 72% (95% CI, 64% to 78%)
and the OS was 82% (95% CI, 75% to 87%). To verify 1023
as the best cutoff and evaluate the additional impact of
genetic alterations, we performed additional subgroup
analyses within ﬁner subdivisions of MRD (Fig 1). The
difference between the EFS in the patient subgroup with
goodA responses to induction and the EFS in the subgroup
with goodB responses did not reach statistical signiﬁcance
(Fig 2A; 75% v 64%; P = .102). The CIR was similar in both
subgroups, but CID was signiﬁcantly higher in patients with
goodB responses (Fig 2B; P = .024). Therapy-related
deaths were more frequent in patients who received allo-
HSCT (2 of 21; 9.5%) than in patients who did not receive
allo-HSCT (5 of 154 [3.3%]; P = .017), with both patient
subgroups containing similar percentages of patients who
underwent allo-HSCT (11% v 14%; P = .622). OS was
similar in both patient subgroups (Fig 2C).
The site of relapse modiﬁed the effect on survival: in pa-
tients with relapses restricted only to the bone marrow, EFS
was signiﬁcantly different between goodA and goodB re-
sponders (79% v 61%; P = .023), whereas it did not differ in
patients with extramedullary plus bone marrow involvement
(Data Supplement). Fewer patients with goodA response to
induction treatment had relapses harboring an IKZF1 de-
letion compared with patients with goodB responses (Fig 3;
17% v 42%; P = .001). Within the goodB responders with
an adverse event, leukemias harboring IKFZ1 deletions
form a cluster, co-occurring with deletions in PAX5 or ETV6
or mutations in BTG1 or TP53 (Fig 3). TP53 aberrations
were the only adverse parameter independently associated
with EFS in multivariable analyses of MRD good responders
(Table 2) that included covariates associated with MRD
response to induction and survival previously identiﬁed in
univariable analyses (Table 1; Data Supplement).
Prognostic Subgroups in Poor Responders to Induction:
PoorA Response (MRD ‡ 1023 to < 1022) Versus PoorB
Response (MRD ‡ 1022)
Patients who responded poorly to induction treatment
(MRD$ 1023) had EFS of 65% (95% CI, 57% to 71%) and
TABLE 2. Final Multivariable Cox Regression Models for EFS
Response to Induction Treatment No. of Patients HR 95% CI P
Good response
All
TP53 loss/mutation
No 120 1.00
Yes 12 3.37 1.48 to 7.68 .004
Isolated bone marrow relapses
TP53 mutation
Wild-type 86 1.00
Mutation 6 4.38 1.03 to 7.27 .007
Poor response
All
MRD $ 1023 to , 1022 53 1.00
MRD $ 1022 53 2.40 1.23 to 4.65 .010
TP53 loss
Diploid 102 1.00
Loss 4 4.51 1.33 to 15.25 .016
Isolated bone marrow relapses
MRD $ 1023 to , 1022 69 1.00
MRD $ 1022 81 1.96 1.11 to 3.46 .020
All good and poor responders
MRD , 1024 95 1.00
MRD $ 1024 to , 1023 37 1.47 0.76 to 2.83 .26
MRD $ 1023 to , 1022 57 0.93 0.49 to 1.80 .84
MRD $ 1022 56 2.33 1.35 to 4.01 .002
TP53 loss/mutation
No 225 1.00
Yes 20 2.51 1.32 to 4.78 .005
Isolated bone marrow relapses
MRD , 1024 85 1.00
MRD $ 1024 to , 1023 45 2.06 1.06 to 3.99 .033
MRD $ 1023 to , 1022 69 1.39 0.72 to 2.70 .33
MRD $ 1022 81 2.80 1.57 to 5.00 0
NOTE. Cox regression analysis was performed as stepwise forward testing.
Models were compared using the log likelihood-ratio test. All variables that reached
signiﬁcance in univariable survival analysis were included: allogeneic
hematopoietic stem cell transplantation donor in poor response group;
ETV6-RUNX1; BCR-ABL; high hyperdiploidy; hypodiploidy; and TP53 mutation,
deletion, or both, if both signiﬁcant. The following are all variables that reached
signiﬁcance in the distribution between minimal residual disease subgroups: time
to relapse, IKZF1 loss, and CDKN2A or CDKN2B loss.
Abbreviations: EFS, event-free survival; HR, hazard ratio; MRD, minimal residual
disease.
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FIG 4. Survival difference between two subgroups of poor responders to induction. The left panel shows the intention to treat (receive allogeneic
hematopoietic stem-cell transplantation [allo-HSCT]) analyses and the right panel shows the analyses for patients who received allo-HSCT. (A) Kaplan-
Meier analysis comparing the 10-year event-free survival (EFS) in poor responders to induction therapy. (B) Competing (continued on following page)
Journal of Clinical Oncology 3501
Improving Stratiﬁcation in Late Bone Marrow BCP-ALL Relapses
Downloaded from ascopubs.org by Universitaet Zuerich on December 20, 2019 from 130.060.047.120
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
OS of 74% (95% CI, 67% to 80%). To identify new
prognostic response groups and evaluate the additional
impact of genetic alterations, subgroup analyses were
carried out with ﬁner MRD-based subdivisions of poor
response to induction (Fig 1). EFS was signiﬁcantly superior
in patients with poorA response to induction compared with
patients with poorB response (Fig 4A; 74% v 56%; P = .02).
This difference in EFS was the result of signiﬁcantly more
subsequent relapses occurring in poorB responders
(Fig 4B). OS did not signiﬁcantly differ between patients
with poorA or poorB responses to induction (Fig 4C). Both
subgroups of poor responders who received allo-HSCT had
favorable outcomes (Fig 4; EFS, 81% v 68%; OS, 84% v
76%). In contrast, poor responders who did not receive
allo-HSCT had very dismal EFS (10%; 95% CI, 3% to 24%)
and OS (41%; 95% CI, 23% to 58%), conﬁrming the
importance of allo-HSCT for this subgroup. Clinical and
genetic characteristics did not signiﬁcantly vary between
poorA and poorB responder subgroups, excepting that re-
lapses more frequently harbored ETV6-RUNX1 fusions in
patients with poorA responses to induction (Fig 3; Data
Supplement). PoorB response to induction was an in-
dependent prognostic marker in multivariable analysis;
however, the ﬁnal prediction model resulting from our
analyses included TP53 loss as independent predictor of
poor outcome as well (Data Supplement). A number of
TP53 mutations were partly overlapping with TP53
losses, but separately, they did not reach statistical sig-
niﬁcance. Our results conﬁrm that outcome in patients
responding poorly to induction for late bone marrow
ALL relapses is improved by intensifying treatment
with allo-HSCT. Except for rare TP53 losses, the panel of
genetic markers assessed is not of additional prognostic
value.
Impact and Prediction of MRD Levels Before Allo-HSCT
High MRD values directly before HSCT have previously
been shown to have prognostic value for patients with
ALL.16 Our trial data included MRD assessment in bone
marrow samples collected after induction treatment and
30 days or fewer before allo-HSCT. We veriﬁed in our cohort
that MRD at 30 days or fewer before allo-HSCT predicted
poor survival in patients with late bone marrow ALL re-
lapses; EFS was worse in patients with MRD of 10–3 or
greater (late nonresponders) compared with patients with
MRD of less than 10–3 before allo-HSCT (50% v 81%; P =
.016), whereas EFS was remarkably good in patients in
whom MRD was reduced to less than 1024 before allo-
HSCT (Fig 5A; 84%). Correspondingly, patients with MRD
of 10–3 or greater before allo-HSCT were 4.9-fold more likely
to suffer a subsequent event after allo-HSCT than those
with MRD of less than 1024 (Data Supplement). CIR, but
not CID, was signiﬁcantly higher in patients with MRD of
10–3 or greater before allo-HSCT than in patients with MRD
of less than 10–3 (Fig 5B). Ninety-one percent of patients
who responded poorly to induction reached MRD levels of
less than 10–3 before allo-HSCT, and 80% even reached
MRD levels of less than 1024 (Fig 5D).
We then investigated the predictive power of MRD as-
sessment after induction treatment for high MRD values
immediately before allo-HSCT. The proportion of patients
who reachedMRD of less than 10–3 (83%) or even less than
1024 (59%) before allo-HSCT was signiﬁcantly lower in the
subgroup of patients with MRD of 1022 or greater than in
patients with MRD of 10–3 or greater to MRD of less than
1022 after induction (Fig 5E; Data Supplement; 96% and
83%, respectively; P = .037). Collectively, MRD of 1022 or
greater after induction predicted MRD persistence at levels
of 1023 or greater and 1024 or greater before allo-HSCT,
which was associated with signiﬁcantly poorer EFS and
a higher incidence of relapse after allo-HSCT.
DISCUSSION
Our study assesses the prognostic value of ﬁner MRD-
based response groups and genetic alterations in patients
with late bone marrow BCP-ALL relapses who were uni-
formly treated within the ALL-REZ BFM 2002 trial and the
subsequent ALL-REZ BFM Registry. In this substantially
enlarged cohort with long-term follow-up, we reliably
conﬁrm that MRD-based stratiﬁcation using the established
1023 MRD cutoff produces excellent EFS and OS for pa-
tients with late bone marrow relapses.9
Generally, the types of agents in induction treatment and
their dosages determine the proportion of patients in whom
MRD is reduced to below a certain prognostically valuable
cutoff level after induction.2,9,17 Patients in the ALLR3 trial
received an anthracycline-based more intensive induction
than patients in the ALL-REZ BFM 2002 trial. In that trial,
a lower cutoff of 1024 was deﬁned for MRD-based allo-
HSCT indication in patients with late bonemarrow BCP-ALL
relapses.2,18 It was recently shown in a cohort of 228 pa-
tients in the ALLR3 trial that chemotherapy alone produced
a favorable outcome in patients with MRD of less than 1024
after induction.18 Among patients in the ALL-REZ BFM
2002 trial with relapses restricted to only the bone marrow,
EFS was signiﬁcantly lower in the subgroup with MRD from
1024 or greater to less than 1023 (goodB) versus MRD of
less than 1024 (goodA) after induction. So the question
arises of whether goodB responders would beneﬁt from
FIG 4. (Continued). risk analysis of cumulative incidence of subsequent relapses (CIR) and cumulative incidence of treatment-related deaths (CID) at
10 years in patients who responded poorly to induction therapy. (C) Kaplan-Meier analysis comparing the 10-year overall survival (OS) in poor
responders to induction therapy. Minimal residual disease (MRD) in bone marrow was used to more ﬁnely divide poor response into two subgroups
(MRD , 1022 to $ 1023 and MRD $ 1022) after induction therapy.
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FIG 5. Minimal residual disease (MRD) before allogeneic hematopoietic stem-cell transplantation (allo-HSCT) predicts survival and its kinetics after
completion of induction treatment. (A) Kaplan-Meier analysis estimating the 10-year event-free survival (EFS) among patient subgroups grouped according to
the level of MRD that was reached immediately before allo-HSCT. (B) The corresponding competing risk analysis of cumulative incidence of subsequent
relapses (CIR) and cumulative incidence of treatment-related deaths (CID) at 10 years in the same MRD-based patient subgroups described in panel A. (C)
Kaplan-Meier analysis estimating the 10-year overall survival (OS) in the same patient subgroups as in panel A. Only patients (continued on following page)
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treatment intensiﬁcation with allo-HSCT in CR2. The higher
proportion of therapy-related deaths among goodB re-
sponders is partly related to the small number of patients in
whom allo-HSCT was performed. We interpret the similar
OS between goodB and goodA responders as a justiﬁcation
to intensify with allo-HSCT only after second relapse rather
than assigning all goodB responders to receive allo-HSCT
within the ﬁrst relapse treatment by decreasing the MRD-
based cutoff to 1024 (Data Supplement). Thus, we do not
advise lowering the MRD cutoff for allo-HSCT to 1024 in
patients treated according to the ALL-REZ BFM 2002
strategy.
Excellent outcomes (EFS and OS. 80%) were achieved in
patients with MRD of 10–3 or greater to MRD of less than
1022 after induction treatment who received allo-HSCT in
CR2, which has not been observed in other trials18 and
which suggests that there is not an urgent need for addi-
tional treatment intensiﬁcation in these patients. In com-
parison, patients with MRD of 1022 or greater who received
allo-HSCT in CR2 had signiﬁcantly worse outcomes. The
prognostic relevance of MRD before allo-HSCT in our co-
hort corroborated data reported by Bader et al16 for
intermediate-risk relapses using the 1024 MRD cutoff. MRD
persisted at 1024 or greater until before allo-HSCT signif-
icantly more frequently in the subgroup with MRD of 1022
or greater than with MRD of 10–3 or greater to MRD of less
than 1022 after induction. Thus, patients with MRD of 1022
or greater may beneﬁt from novel postinduction treatment
approaches, which should be prospectively investigated in
future controlled trials. But interestingly, patients with MRD
of 1024 or greater and even 1023 or greater before allo-
HSCT unexpectedly had a relatively good prognosis after
allo-HSCT in our cohort and clearly seem to beneﬁt from an
allo-HSCT. Even so, this patient group in our cohort had
a particularly poor prognosis. We deﬁned them as late
nonresponders and will classify nonresponse as an adverse
event in future trials. These late nonresponders would be
eligible for prospective phase I/II trials or salvage therapies
with drugs having other mechanisms of action before allo-
HSCT, such as immunotherapeutics (ie, by targeting
CD19), small molecules, or a combination thereof. We
identiﬁed patients with 25% or more leukemic blasts after
induction as the early nonresponder subgroup with the
lowest chance to survive. These patients should be re-
moved from the trial directly after induction and enrolled in
phase I/II trials or receive individual, potentially targeted,
treatment recommendations.
We identiﬁed TP53 alterations (mutations and/or deletions)
as the only genetic marker independently associated with
poor outcome in the different response groups of late bone
marrow ALL relapses. TP53 mutations resulting in a dys-
functional mutant protein could be directly targeted and
functionally restored by the APR-246 compound, a po-
tentially attractive strategy to pursue in future research.19-21
Other genetic alterations associated with poor outcome in
newly diagnosed or relapsed ALL, such as IKZF1+,22 KRAS
mutations,14,21 or IKZF1 or PAX5 deletions,18 are either rare
in our comparably favorable-risk cohort and thus they are of
little prognostic relevance or were not associated with
prognosis in our cohort. The only exception here is the
presence of hypodiploidy,13 which mainly overlaps with the
occurrence of TP53 mutations or deletions in our cohort.
A more comprehensive genetic characterization using
genome-wide technologies, such as RNA sequencing,
epigenetic approaches, and high-density single nucle-
otide polymorphism arrays in large collaborative studies
for children with ALL relapses may identify new genetic
and epigenetic characteristics predicting response to
induction or associated with survival. Ideally, those
markers may serve as suitable novel targets for signal
transduction inhibitors or immunotherapeutics.22-24
We conclude that the ALL-REZ BFM approach for MRD
response-adapted allo-HSCT stratiﬁcation in patients with
late bone marrow BCP-ALL relapses is very effective and
results in stably improved long-term survival probabilities of
more than 70%. New late bone marrow BCP-ALL relapse
trials should continue to apply MRD response-based in-
dication for allo-HSCT in CR2 using the established
prognostic cutoff according to induction intensity. Prog-
nosis could be further improved by controlled protocol-
based treatment intensiﬁcation in patients with MRD
of 1022 or greater after induction and in patients with TP53
alterations at relapse independently of MRD-based
response.
FIG 5. (Continued). who received allo-HSCT are included in the analyses. (D) Each bar shows the proportion of patients assigned to each of the fourmore ﬁnely
deﬁned MRD categories. Bars compare the MRD kinetics in patients with bone marrow relapses of B-cell precursor acute lymphoblastic leukemia during
treatment at the six indicated sequential bonemarrow collection times between completion of induction treatment and 30 days or fewer before allo-HSCT. The
following are details for the x-axis labels: after induction (after 2 and 4 weeks of treatment); during consolidation 1 (after 6 weeks of treatment); during
consolidation 2 (after 9 weeks of treatment); after consolidation treatment 1 (after 11 weeks of treatment); after consolidation treatment 2 (after 13 weeks of
treatment); and before allo-HSCT (after 15 weeks of treatment and 30 days or fewer before allo-HSCT). (E) Each bar shows the proportion of patients with the
three MRD response levels indicated by color. The two bars compare patients with MRD $ 1022 (left) and patients with MRD $ 1023 to , 1022 (right) after
induction at the time point 30 days or fewer before allo-HSCT. The pie chart in the center shows the proportion of patients with MRD$ 1022 (purple) andMRD
$ 1023 to , 1022 (orange) response to induction.
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